GeoVax to Participate in Upcoming Industry Meetings
2023年5月25日 - 10:00PM
via NewMediaWire -- GeoVax Labs, Inc. (Nasdaq: GOVX), a
biotechnology company specializing in developing human vaccines and
cancer immunotherapies, announced today that its Chief Medical
Officer, Kelly T. McKee, M.D., will participate in the American
Society of Clinical Oncology (ASCO) 2023 Annual Meeting, in Chicago
on June 2-6, 2023, and its Chairman and CEO, David Dodd, and other
senior management will participate in the 2023 BIO International
Convention (BIO), in Boston on June 5-8, 2023. Details for the
events are as follows:
2023 ASCO Annual Meeting
Date: June 2-6, 2023Location: McCormick Place,
ChicagoRegistration: https://conferences.asco.org/am/registrationMeeting
Interest: Contact management directly at
info@geovax.com
Dr. McKee will meet with interested parties at ASCO to discuss
progress in the clinical development of Gedeptin®, an
adenovirus-vectored bacterial purine phosphorylase, designed to
locally activate a systemically administered chemotherapeutic
prodrug that is currently in a Phase 2 study for the treatment of
advanced head and neck cancer.
2023 BIO International Convention
Date: June 5-8, 2023Location: Boston Convention and Exhibition
CenterRegistration: https://www.bio.org/events/bio-international-convention/registration-information Meeting
Interest: Use BIO’s scheduling platform or contact management
directly at info@geovax.com
Mr. Dodd and other senior management will host one-on-one
meetings with registered attendees to explore collaborative and
strategic opportunities around the company’s development portfolio,
including Gedeptin® as well as GEO-CM04S1, a multi-antigenic,
next-generation COVID-19 vaccine currently being investigated in
two Phase 2 clinical trials.
About GeoVax
GeoVax Labs, Inc. is a clinical-stage biotechnology company
developing novel therapies and vaccines for solid tumor cancers and
many of the world’s most threatening infectious diseases. The
company’s lead program in oncology is a novel oncolytic solid tumor
gene-directed therapy, Gedeptin®, presently in a multicenter Phase
1/2 clinical trial for advanced head and neck cancers. GeoVax’s
lead infectious disease candidate is GEO-CM04S1, a next-generation
COVID-19 vaccine targeting high-risk immunocompromised patient
populations. Currently in two Phase 2 clinical trials, GEO-CM04S1
is being evaluated as a COVID-19 vaccine for immunocompromised
patients such as those suffering from hematologic cancers and other
patient populations for whom the current authorized COVID-19
vaccines are insufficient. In addition, GEO-CM04S1 is in a Phase 2
clinical trial evaluating the vaccine as a more robust, durable
COVID-19 booster among healthy patients who previously received the
mRNA vaccines. GeoVax has a leadership team who have driven
significant value creation across multiple life science companies
over the past several decades. For more information, visit our
website: www.geovax.com.
Investor Relations Contact:
Rich CockrellCG Capital404-736-3838 govx@cg.capital
GeoVax Labs (NASDAQ:GOVXW)
過去 株価チャート
から 4 2024 まで 5 2024
GeoVax Labs (NASDAQ:GOVXW)
過去 株価チャート
から 5 2023 まで 5 2024